[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bangladesh Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":294},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,74,100,124,152,179,200,234,257,275],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642090","coeliac-plexus-vs-splanchnic-nerve-neurolysis-for-upper-abdominal-cancer-pain-100642090",false,"NCT07653906","Coeliac Plexus vs Splanchnic Nerve Neurolysis for Upper Abdominal Cancer Pain","Effect of Coeliac Plexus Versus Splanchnic Nerve Neurolysis in Pain Management With Upper Abdominal Malignancies","Inclusion Criteria:\n\n* Adult patient\n* Both genders\n* Diagnosed case of upper abdominal malignancy (pancreatic, gastric, hepatic, or biliary origin)\n* Experiencing moderate to severe pain (≥5 on a 10 point visual analog scale)\n* Patients who are conscious and can communicate\n* No Contraindication for nerve block (e.g., coagulopathy, anticoagulant drugs)\n\nExclusion Criteria:\n\n* Previous coeliac plexus block, splanchnic nerve block, or major abdominal nerve ablation\n* Severe spinal deformities or anatomical distortion at the coeliac plexus or splanchnic nerve site\n* Local or systemic infection at or near the block site\n* Known allergy to local anesthetics or neurolytic agents\n* Pregnancy\n* Lactating mother\n* Cognitive impairment or psychiatric illness","ALL","18 Years",{"count":19,"type":20},44,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to determine whether Neurolytic Splanchnic Nerve Block (NSNB) reduces pain in adults with upper abdominal malignancies. It will also evaluate the safety of Neurolytic Splanchnic Nerve Block (NSNB). The main questions it aims to answer are:\n\nDoes NSNB reduce pain intensity compared to Neurolytic Coeliac Plexus Block (NCPB), as measured by the Visual Analog Scale (VAS)? What adverse effects do participants experience when receiving Neurolytic Splanchnic Nerve Block (NSNB)?\n\nInvestigators will compare Neurolytic Splanchnic Nerve Block (NSNB) with Neurolytic Coeliac Plexus Block (NCPB) to determine which intervention provides more effective and safer pain relief.\n\nParticipants will:\n\n* receive either NSNB or NCPB under fluoroscopic guidance\n* be monitored immediately and for 2 hours after the procedure for any complications Have their pain intensity recorded immediately after the procedure, and at 7 days, 1 month, and 3 months\n* be evaluated for quality-of-life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 3 (EORTC QLQ-C30) at 1 month and 3 months.\n* have their opioid consumption tracked throughout the study.",[26,27,28],"Abdominal Neoplasms","Pain Management","Neurolytic Techniques",[30,31,32,33],"Upper abdominal cancer","Splanchnic nerve block","Coeliac plexus block","Analgesic efficacy","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2026-05-01",{"date":42,"type":20},"2027-01-31",{"name":44,"class":45},"Bangladesh Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100636021","efficacy-of-ultrasound-guided-erector-spinae-block-for-postoperative-pain-management-in-nephrectomy-100636021","NCT07560267","Efficacy of Ultrasound-Guided Erector Spinae Block for Postoperative Pain Management in Nephrectomy","Efficacy of Ultrasound-Guided Erector Spinae Plane Block in Postoperative Pain Management in Nephrectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged 18 to 64 years\n* Scheduled for open nephrectomy (radical or partial) under general anesthesia\n* ASA physical status I-II (American Society of Anesthesiologists classification)\n\nExclusion Criteria:\n\n* Allergy to local anesthetics.\n* Local infection or inflammation at the site of the Block placement.\n* Presence of anatomical deformities in the spine\n* Coagulopathy or any bleeding disorder.\n* Pregnancy or breastfeeding women.\n* History of severe chronic pain syndrome","64 Years",{"count":56,"type":20},66,[23],"This clinical trial aims to evaluate the effectiveness of the ultrasound-guided erector spinae plane (ESP) block in managing postoperative pain for patients undergoing open nephrectomy (kidney removal surgery). The study will compare this new technique to traditional pain management methods, such as opioid medications, to assess whether the ESP block reduces pain and the need for opioids after surgery.\n\nPatients will be randomly assigned to one of two groups:\n\nGroup C will receive conventional pain relief methods, including opioids. Group E will receive the ultrasound-guided ESP block in addition to general anesthesia.\n\nThe main goals are to determine:\n\nHow much pain relief each method provides, measured using a visual analog scale (VAS).\n\nThe total amount of opioids required during the first 24 hours post-surgery.\n\nAdditional measurements will include monitoring vital signs like heart rate, blood pressure, and oxygen levels.\n\nThis study will help find safer and more effective ways to manage pain after nephrectomy, reducing the reliance on opioids and improving patient recovery",[60,61,62],"Erector Spinae Plane Block","Nephrectomy","Postoperative Pain",[64,65,66,61],"Erector Spinae Plane Block (ESP)","Postoperative Pain Management","Opioid Consumption","2026-04-24",{"date":40,"type":38},{"date":70,"type":38},"2025-09-01",{"date":72,"type":20},"2026-07-30",{"name":44,"class":45},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100631127","effect-of-scalp-block-on-intraoperative-hemodynamics-and-postoperative-pain-in-craniotomy-patients-100631127","NCT07496632","Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients\"","Efficacy of Scalp Block on Intraoperative Hemodynamic Responses and Postoperative Analgesia in Patients Undergoing Craniotomy","Inclusion Criteria:\n\n* Age 18-64 years.\n* ASA (American Society of Anesthesiologists) physical status I or II.\n* Patients scheduled for elective supratentorial craniotomy.\n* BMI of 18 to 30 kg\u002Fm².\n* GCS score of 9 to 15.\n\nExclusion Criteria:\n\n* Patient with instable blood pressure and heart rate.\n* Known allergy or hypersensitivity to local anesthetics.\n* Coagulation disorders or current anticoagulant therapy.\n* Infection at the injection site or systemic infection.\n* Patients with open skull defects.",{"count":82,"type":20},72,[23],"The goal of this clinical trial is to learn if an ultrasound-guided scalp block can improve intraoperative hemodynamic stability and provide better postoperative pain relief in adult patients undergoing elective supratentorial craniotomy. The main questions it aims to answer are:\n\nDoes ultrasound-guided scalp block reduce changes in heart rate and blood pressure during surgery compared with surgical site infiltration?\n\nDoes ultrasound-guided scalp block decrease postoperative pain and opioid requirements in the first 24 hours after craniotomy?\n\nResearchers will compare patients receiving an ultrasound-guided scalp block to those receiving standard surgical site infiltration to see if the scalp block provides better perioperative hemodynamic control and postoperative analgesia.\n\nParticipants will:\n\nReceive general anesthesia with either ultrasound-guided scalp block or surgical site infiltration\n\nHave heart rate, blood pressure, and other hemodynamic parameters monitored throughout surgery\n\nReceive standard postoperative pain management, with pain scores recorded at 0, 2, 6, 12, and 24 hours\n\nReceive opioids as needed based on pain scores, with total opioid consumption and time to first analgesic dose recorded\n\nBe monitored for adverse events, including nausea, vomiting, sedation, and block-related complications",[86],"Scalp Block",[86,88,89,90],"Intraoperative Hemodynamic Responses","Postoperative Analgesia","Craniotomy","NOT_YET_RECRUITING","2026-03-27",{"date":94,"type":38},"2026-04-01",{"date":96,"type":20},"2026-04",{"date":98,"type":20},"2026-10",{"name":44,"class":45},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":46},"100629922","comparison-of-platelet-rich-plasma-and-prolotherapy-for-plantar-fasciitis-100629922","NCT07480967","Comparison of Platelet-Rich Plasma and Prolotherapy for Plantar Fasciitis","Efficacy Of Platelet Rich Plasma Therapy Versus Prolotherapy In Patients With Plantar Fasciitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patient with plantar fasciitis not responding to conservative therapy.\n\nExclusion Criteria:\n\n* Patients with uncontrolled diabetes, haematological disorders, hepatitis B or C, HIV, clinical signs of acute inflammation, or septicaemia.\n\n  * Those receiving local steroid injections within one month.\n  * Those receiving non-steroidal anti-inflammatory medications within 72 hours.\n  * Platelet levels 25% below the normal level.\n  * Patient who had acute ankle or foot trauma, a diagnosis of calcaneal fracture, or stress fracture.",{"count":108,"type":20},68,[23],"This randomized controlled trial evaluates the comparative effectiveness of platelet-rich plasma (PRP) therapy and prolotherapy in patients with plantar fasciitis. Both interventions are commonly used regenerative injection therapies intended to improve pain and functional outcomes in patients who do not respond adequately to conventional conservative treatments.\n\nParticipants diagnosed with plantar fasciitis will be randomly assigned to receive either PRP injection or prolotherapy. The results of this study aim to identify the more effective injection therapy for improving clinical outcomes in patients with plantar fasciitis",[112],"Planter Fasciitis",[114,115,116],"Planter fasciitis","Prolotherapy","Platelet Rich Plasma","2026-03-18",{"date":119,"type":38},"2026-03-20",{"date":94,"type":20},{"date":122,"type":20},"2027-02-28",{"name":44,"class":45},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100627653","phase-4-efficacy-and-safety-of-mirogabalin-in-diabetic-peripheral-neuropathic-pain-100627653","NCT07451431","Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain","Efficacy, Safety and Patient-Reported Outcomes of Mirogabalin in Diabetic Peripheral Neuropathic Pain","Inclusion Criteria:\n\n* Adults (≥40 years) with diabetic neuropathy (Toronto score ≥6).\n* Persistent pain (NPS) despite standard therapy.\n* Stable diabetes management (HbA1c ≤8.5%).\n\nExclusion Criteria:\n\n* History of drug allergy to gabapentinoids.\n* Concurrent use of opioids or other neuropathic pain medications.\n* Pregnancy or lactation.\n* Cancer pain\n* Entraptment Radioculopathy","40 Years",{"count":133,"type":20},78,[135],"PHASE4","The goal of this clinical trial is to learn if drug Mirogabalin works to treat diabetic peripheral neuropathic pain in adults. It will also learn about the safety of the drug Mirogabalin. The main questions it aims to answer are:\n\nDoes drug mirogabalin reduce neuropathic pain intensity? Is the drug mirogabalin safe in patients with diabetes suffering from neuropathic pain? Does drug mirogabalin improve patients' quality of life (QoL) ( physical, mental, and social well-being)? Researchers will compare drug mirogabalin to drug pregabalin (a drug conventionally used to treat diabetic neuropathic pain) to see if drug mirogabalin works to treat, safe and improve quality of life (QoL) in diabetic neuropathic pain.\n\nParticipants will:\n\nTake drug Mirogabalin or pregabalin every day for 8 weeks Visit the clinic at 1, 2, 4, 6, 8 weeks for checkups",[138],"Diabetic Peripheral Neuropathic Pain (DPNP)",[140,141,142,143],"Mirogabalin","Diabetic Peripheral Neuropathic Pain","Safety","Efficacy","2026-03-06",{"date":146,"type":38},"2026-03-09",{"date":148,"type":38},"2025-10-01",{"date":150,"type":20},"2027-05",{"name":44,"class":45},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100625772","community-hypertension-control-using-the-health-belief-model-and-precede-proceed-100625772","NCT07426978","Community Hypertension Control Using the Health Belief Model and PRECEDE-PROCEED","Application of the Health Belief Model Using the PRECEDE-PROCEED Framework for Community-Based Hypertension Control: A Cluster Randomized Trial","HBM-HTN-CRT","Inclusion Criteria:\n\n* Are aged 18 years or older.\n* Have physician-diagnosed hypertension or documented systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg on at least two screening occasions.\n* Have resided in the cluster for at least 6 months and plan to remain during the study period.\n* Are able to provide informed consent.\n\nExclusion Criteria:\n\n* Severe cognitive impairment, serious comorbidities requiring intensive care (such as advanced cancer or end-stage renal disease), and current pregnancy or intention to become pregnant within 12 months.",true,{"count":162,"type":20},480,[23],"This protocol describes a community-based cluster randomized controlled trial in Kamalgonj Upazila, Moulvibazar district, Bangladesh, evaluating a theory-driven intervention to improve blood pressure (BP) control among adults with hypertension. The intervention is grounded in the Health Belief Model (HBM) and structured using the PRECEDE-PROCEED framework to address behavioural and structural barriers such as poor medication adherence, high salt intake, physical inactivity, inadequate fruit intake, tobacco use, fragmented care and limited access to affordable medicines.\n\nFormative mixed-methods research in the study communities showed high levels of uncontrolled hypertension despite treatment, frequent non-adherence, unhealthy diet and activity patterns, heavy smokeless tobacco use and reliance on informal providers. These findings informed the PRECEDE phases (social, epidemiological, behavioural\u002Fenvironmental, educational\u002Fecological and administrative\u002Fpolicy assessments) and the selection of intervention targets.\n\nTwelve clusters (villages or wards of about 3,000-5,000 residents) will be randomised 1:1 to intervention or control, with around 40 participants per cluster (≈480 in total). Adults are eligible if they are ≥18 years, have physician-diagnosed hypertension or BP ≥140\u002F90 mmHg on two occasions, have lived in the cluster ≥6 months and can provide informed consent; exclusions include severe comorbidities requiring intensive care, severe cognitive impairment and pregnancy or planned pregnancy within 12 months. Randomisation is stratified by urban\u002Frural status and performed by an independent statistician, with outcome assessors and data analysts blinded where feasible. The sample size was calculated to detect a 5-7 mmHg difference in mean systolic BP at 12 months with 80% power, assuming a standard deviation of 20 mmHg, intracluster correlation of 0.02-0.05 and up to 15% loss to follow-up.\n\nThe intervention consists of four components delivered over 12 months by trained community health workers. Group education includes four bi-weekly 45-60-minute sessions on understanding hypertension, benefits of BP control, practical medication-adherence strategies and lifestyle modification (salt reduction, physical activity, healthy eating and tobacco cessation), using interactive methods and local success stories to influence perceived threat, benefits, barriers, cues to action and self-efficacy. Individual counselling and motivational interviewing (two one-to-one sessions at weeks 4 and 8) identify personal barriers, set SMART goals and build confidence for daily self-management.\n\nEnabling strategies include community BP monitoring corners equipped with automated devices, reminder calendars with tick-boxes, pictorial Bengali leaflets on low-salt recipes and exercise, wallet cards summarising key messages, and linkages to affordable generic antihypertensives and government essential drug programmes, including collaboration with local pharmacy sellers and village doctors where feasible. Reinforcing strategies involve inviting family members to at least one group session, monthly follow-up calls or home visits from months 3-12 to provide encouragement and problem-solving, facilitation of informal peer support or walking groups, and public recognition or certificates for participants who achieve BP control or sustained behaviour change. Control clusters receive usual care without structured HBM-based education or community follow-up, and will be offered a condensed version of the intervention after 12-month follow-up.\n\nData are collected at baseline, 6 months and 12 months. Primary outcomes are change in mean systolic BP from baseline to 12 months and the proportion of participants with controlled BP (systolic \\\u003C140 mmHg and diastolic \\\u003C90 mmHg) at 12 months. Secondary outcomes include change in mean diastolic BP, BP control at 6 months, HBM construct scores, medication adherence measured with the Bangladesh Medication Adherence Scale, lifestyle behaviours (salt intake, physical activity, fruit and vegetable consumption, tobacco use), knowledge of hypertension and health-service utilisation (clinic visits, BP monitoring frequency and source of BP checks). BP is measured by trained data collectors using validated automated oscillometric devices following WHO\u002FISH guidelines, with two seated readings averaged at each visit.\n\nProcess evaluation will assess fidelity, reach, dose, acceptability and contamination using attendance registers, facilitator checklists, supervision forms, questionnaires and qualitative interviews. Impact evaluation will examine changes in HBM constructs, adherence, behaviours, knowledge and service use at 6 and 12 months, while outcome",[166],"Hypertension",[166,168,169,170],"Health Belief Model","PRECEDE-PROCEED","Bangladesh","2026-02-16",{"date":173,"type":38},"2026-02-23",{"date":175,"type":20},"2027-01",{"date":177,"type":20},"2028-01",{"name":44,"class":45},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":46},"100624374","comparison-of-response-between-combination-of-transarterial-chemoembolization-and-lenvatinib-therapy-versus-lenvatinib-monotherapy-in-patients-with-unresectable-hepatocellular-carcinoma-100624374","NCT07408804","Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age 18-75 years,\n2. Hepatocellular carcinoma, confirmed by dynamic CT scan \u002F MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,\n3. At least one measurable lesion based on mRECIST criteria,\n4. ECOG performance status 0-2,\n\nExclusion Criteria:\n\n1. Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,\n2. Hepatocellular carcinoma with main trunk portal vein thrombosis,\n3. Child Turcotte Pugh Score 10 ( C) or more,\n4. ALBI grade 3,\n5. Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,\n6. Known allergy or intolerance to lenvatinib .","75 Years",{"count":187,"type":20},40,[23],"The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.",[191],"Unresectable Hepatocellular Carcinoma (HCC)","2026-02-06",{"date":194,"type":38},"2026-02-13",{"date":196,"type":38},"2025-04-08",{"date":198,"type":20},"2026-09-30",{"name":44,"class":45},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":207,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":46},"100600349","effect-of-vitamin-d3-on-brain-waves-in-male-parkinsons-patients-with-low-vitamin-d-a-qeeg-study-100600349","NCT07096336","Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study","Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis","Inclusion Criteria:\n\n* Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale\n* Age: 51years to70 years\n* BMI: 18.5-24.9 kg\u002Fm2\n* Hypovitaminosis D (Serum 25(OH)D level \\\u003C30 ng\u002Fml)\n* Patients on Levodopa therapy\n\nExclusion Criteria:\n\n* Already taking vitamin D3 supplements\n* Current use of medication\u002Fsubstances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol.\n* Patients who are currently suffering from following diseases\n\n  * Neurological disorders (Migraine, epilepsy)\n  * Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure)\n  * Respiratory disorders (Bronchial asthma, COPD)\n  * Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia)\n* With biochemical evidence of-\n\n  * Hypercalcemia\n  * Renal insufficiency\n  * Liver diseases\n  * Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism)\n* Active smoker","MALE","51 Years","70 Years",{"count":211,"type":20},15,[23],"This is an experimental study (Interventional self-controlled trial, pretest-posttest design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male Parkinson's disease patients with hypovitaminosis D.\n\nThe main question it aims to answer is:\n\nVitamin D3 supplementation has effect on brain waves in male Parkinson's disease patients with hypovitaminosis D.\n\nResearcher will compare the effect of vitamin D3 supplementation on brain waves in male Parkinson's disease patients with hypovitaminosis D with their pre intervention ( baseline ) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG).\n\nParticipants will :\n\nTake vitamin D3 orally for 8 weeks (50,000 IU\u002Fweek) Visit the medical university after 8 weeks for evaluation of serum 25(OH)D level and QEEG Must bring the empty strips of vitamin D supplement with them during their visit.",[215],"PARKINSON DISEASE (Disorder)",[217,218,219,220,221,222,223,224,225],"Parkinson's disease","Vitamin D3","Quantitative EEG (qEEG)","Brain wave","25-hydroxyvitamin D","Spectral power","Dopaminergic neurons","EEG frequency bands","Neurodegeneration","2025-07-29",{"date":228,"type":38},"2025-07-31",{"date":230,"type":38},"2025-07-15",{"date":232,"type":20},"2025-11",{"name":44,"class":45},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":207,"minAge":208,"maxAge":209,"enrollmentInfo":241,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":46},"100599446","effect-of-vitamin-d3-supplementation-on-cardiac-autonomic-nerve-function-in-male-parkinsons-disease-patients-with-hypovitaminosis-d-100599446","NCT07084597","Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Parkinson's Disease Patients With Hypovitaminosis D","Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male","IInclusion criteria:\n\n* Male patients with of Parkinson's disease diagnosed by neurologist with unilateral or bilateral involvement and mild to moderate disability according to Hoehn and Yahr (H-Y) scale (I-III)\n* Age: 51-70 years\n* BMI: 18.5-24.9 kg\u002Fm2\n* Vitamin D3 deficient or insufficient\n* On Levodopa medication\n\nExclusion criteria:\n\n1. Patients with a history of drug abuse including alcoholism.\n2. Patients on following drugs will be excluded-\n\n   * Antioxidant vitamin supplements\n   * Lipid lowering medications\n   * Antihypertensive drug\n   * Anti-arrhythmic drug\n   * Sedatives\n3. All patients with the history of or clinical manifestation of currently suffering from following diseases \\& condition will be excluded\n\n   * Severe Cardiovascular disorders\n   * Severe neurological disorders\n   * Severe Respiratory disorders\n   * Severe Renal insufficiency (S. Creatinine \\> 1.5 mg\u002Fdl, Acute or chronic kidney disease)\n   * Severe Endocrine disease\n   * Severe Arthritis\n   * Severe Liver diseases\n   * Severe Neoplastic disease\n   * Severe Psychiatric disorder\n   * Current use of iron, zinc, calcium, magnesium and multivitamin supplementation\n   * Already performing yoga or breathing exercise\n   * Hypercalcemia",{"count":211,"type":20},[23],"The goal of this clinical trial is to see the effect of vitamin D3 supplementation on cardiac autonomic nerve function in male Parkinson's disease patients with hypovitaminosis D\n\nMain questions it aims to answer are:\n\n1. Does vitamin D improves heart rate variability(HRV) in male Parkinson's disease patients ?\n2. Does vitamin D improves cardiac autonomic nerve function in male Parkinson's disease patients ? It is a self control trial. Vitamin D3 deficient Parkinson's disease participants will\n\na. undergo through baseline HRV test b. Then they will take vitamin D3 capsule 50000 IU once in a week for 8 consecutive weeks c. Then after intervention with vitamin D supplementation post interventional HRV will be done.\n\nResearcher will compare pre intervention(pre test) and post intervention(post test) value of HRV",[245],"Parkinson Disease",[218,247,248,249],"HRV","Hypovitaminosis D","Parkinson disease","2025-07-24",{"date":226,"type":38},{"date":253,"type":20},"2025-07",{"date":255,"type":20},"2025-10",{"name":44,"class":45},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":207,"minAge":263,"maxAge":131,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":273,"leadSponsor":274,"locationsCount":46},"100599523","effect-of-vitamin-d3-supplementation-on-cardiac-autonomic-nerve-function-in-male-epileptic-patients-with-hypovitaminosis-d-100599523","NCT07085598","Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Epileptic Patients With Hypovitaminosis D","Inclusion Criteria:\n\n* • Diagnosed male patients with Epilepsy by neurologist from the OPD of Department of Neurology by taking proper history of at least two unprovoked (or reflex) seizures occuring \\> 24 hours apart, from patients and eye witnesses.\n\n  * Having hypovitaminosis D (serum vitamin D3 level \\\u003C30 ng\u002Fml)\n  * Age: 20-40 years.\n\n    * Sex: Male\n    * BMI : 18.5-24.9 kg\u002Fm2\n    * Taking antiepileptic drug for 6 months to 2 years ( Enzyme inducer AEDs, e.g. Carbamazepine, Phenytoin, Phenobarbital)\n    * Without medication that affect central nervous system other than antiepileptic drugs (AEDs).\n\nExclusion Criteria:\n\n* • Epileptic patients taking Sodium valproate, oxcarbazepine, Topiramate, Lamotrigine, Levetiracetam.\n\n  * Patient having absence seizure\n  * Alcoholic\n  * Smoker\n  * Patients taking following drugs will be excluded-\n\n    * Anti-diabetic drugs\n    * Antioxidant vitamin supplements\n    * Antihypertensive drug\n    * Anti-arrhythmic drug\n    * Lipid lowering medications\n    * Sedatives\n  * Patients having known hypersensitivity to vitamin D3\n  * All patients with the history of or currently suffering from following diseases \\& condition will be excluded-\n\n    * Cardiovascular disorders (Myocardial infarction, coronary heart disease, cardiac arrhythmia, CCF)\n    * Other neurological disorders (Migraine, stroke)\n    * Respiratory disorders (Bronchial asthma, COPD)\n    * Renal insufficiency (S. Creatinine \\> 1.5 mg\u002Fdl, Acute or chronic kidney disease)\n    * Endocrine disease (Diabetes mellitus, Thyroid disorders- hypothyroidism, hyperthyroidism)\n    * Arthritis (rheumatoid arthritis)\n    * Liver diseases\n    * Neoplastic disease\n    * Psychiatric disorder (schizophrenia, bipolar disorder)\n    * Current use of iron, zinc, calcium, magnesium and multivitamin supplementation\n    * Already performing yoga or breathing exercise\n    * Patients with hypercalcemia","20 Years",{"count":211,"type":20},[23],"The goal of this clinical trial is to see the effect of vitamin D3 supplementation on cardiac autonomic nerve function in male epileptic patients with hypovitaminosis D that weather vitamin D improves heart rate variability or not. The main questions it aims to answer are:\n\n1. Does vitamin D improves cardiac autonomic tone in male epileptic patients?\n2. Does vitamin D improves heart rate variability in male epileptic patients?\n\nIt is a self control trial. Participants will:\n\n1. undergo through baseline HRV testing\n2. start to take vitamin D3 50000 IU once in a week for 8 weeks\n\nb) visit the university after 8 weeks for post interventional HRV testing . Researcher will compare the pre test and post test value of HRV testing.",[268],"Epilepsy",[218,248,247],{"date":271,"type":38},"2025-07-25",{"date":253,"type":20},{"date":255,"type":20},{"name":44,"class":45},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":207,"minAge":263,"maxAge":131,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":283,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":46},"100600355","effect-of-vitamin-d3-supplementation-on-brain-waves-in-male-epileptic-patients-with-hypovitaminosis-d-100600355","NCT07096414","Effect of Vitamin D3 Supplementation on Brain Waves in Male Epileptic Patients With Hypovitaminosis D","Effect of Vitamin D3 Supplementation on Brain Waves in Male Epileptic Patients With Hypovitaminosis D: A Quantitative Electroencephalogram Analysis","Inclusion Criteria:\n\n* Diagnosed male patients with Epilepsy by neurologist from the Out Patient Department of Department of Neurology, BMU by taking proper history of at least two unprovoked (or reflex) seizures occurring \\> 24 hours apart, from patients and eye witnesses.\n* Hypovitaminosis D (\\\u003C30 ng\u002Fml)\n* BMI : 20 - 24 kg\u002Fm²\n* On antiepileptic medication for 6 months to 2 years (enzyme inducing AEDs, e.g. Carbamazepine, Phenytoin, Phenobarbital)\n* Without any medication that affect central nervous system other than antiepileptic drugs (Antidepressants, Antipsychotic, Anxiolytic, Anesthetic drugs)\n* Apparently normal physical health\n\nExclusion Criteria:\n\n* Patients suffering from absence seizure\n* Certain AEDs (Sodium valproate, Ethosuximide, Oxcarbazepine, Topiramate, Lamotrigine, Levetiracetam)\n* Smoker\n* Alcoholic\n* Known hypersensitivity to vitamin D3\n* Patients with hypertension\n* Patient with Thyroid disorder\n* Patient with Diabetes mellitus\n* Patient with Renal Disease\n* Patient with liver Disease\n* Patient with hypercalcemia",{"count":211,"type":20},[23],"This is an experimental study (interventional self-controlled trial, pretest-post test design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male epileptic patients with hypovitaminosis D.\n\n. The main question it aims to answer is:\n\nVitamin D3 supplementation has effect on brain waves in male epileptic patients with hypovitaminosis D.\n\nResearcher will compare the effect of Vitamin D3 supplementation on brain waves in male epileptic patients with hypovitaminosis D with their pre-intervention (baseline) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG).\n\nParticipants will:\n\nTake Vitamin D3 orally for 8 weeks (50,000IU\u002Fweek) Visit the medical university after 8 weeks for evaluation of serum 25 (OH) D level and quantitative electroencephalogram (QEEG) Must bring the empty strips of Vitamin D supplement with them during their visit",[268,248],[268,218,248,287,288],"QEEG","Brainwaves",{"date":228,"type":38},{"date":291,"type":38},"2025-07-19",{"date":255,"type":20},{"name":44,"class":45},""]